Logo image of HEM.CA

HEMOSTEMIX INC (HEM.CA) Stock Fundamental Analysis

TSX-V:HEM - TSX Venture Exchange - CA4236943060 - Common Stock - Currency: CAD

0.095  0 (0%)

Fundamental Rating

0

Overall HEM gets a fundamental rating of 0 out of 10. We evaluated HEM against 22 industry peers in the Biotechnology industry. HEM has a bad profitability rating. Also its financial health evaluation is rather negative. HEM does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

HEM had negative earnings in the past year.
HEM had a negative operating cash flow in the past year.
HEM had negative earnings in each of the past 5 years.
HEM had a negative operating cash flow in each of the past 5 years.
HEM.CA Yearly Net Income VS EBIT VS OCF VS FCFHEM.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2M -4M -6M

1.2 Ratios

HEM has a worse Return On Assets (-1259.00%) than 81.82% of its industry peers.
Industry RankSector Rank
ROA -1259%
ROE N/A
ROIC N/A
ROA(3y)-1012.86%
ROA(5y)-1608.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HEM.CA Yearly ROA, ROE, ROICHEM.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for HEM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HEM.CA Yearly Profit, Operating, Gross MarginsHEM.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, HEM has more shares outstanding
HEM has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, HEM has a worse debt to assets ratio.
HEM.CA Yearly Shares OutstandingHEM.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
HEM.CA Yearly Total Debt VS Total AssetsHEM.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M

2.2 Solvency

Based on the Altman-Z score of -613.80, we must say that HEM is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of HEM (-613.80) is worse than 81.82% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -613.8
ROIC/WACCN/A
WACCN/A
HEM.CA Yearly LT Debt VS Equity VS FCFHEM.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M 4M -4M -6M

2.3 Liquidity

HEM has a Current Ratio of 0.04. This is a bad value and indicates that HEM is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.04, HEM is doing worse than 81.82% of the companies in the same industry.
HEM has a Quick Ratio of 0.04. This is a bad value and indicates that HEM is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.04, HEM is not doing good in the industry: 77.27% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.04
Quick Ratio 0.04
HEM.CA Yearly Current Assets VS Current LiabilitesHEM.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.36% over the past year.
EPS 1Y (TTM)48.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HEM.CA Yearly EPS VS EstimatesHEM.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 -0.05 -0.1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

HEM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HEM.CA Price Earnings VS Forward Price EarningsHEM.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HEM.CA Per share dataHEM.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.01 -0.02 -0.03 -0.04 -0.05

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HEM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HEMOSTEMIX INC

TSX-V:HEM (5/8/2025, 7:00:00 PM)

0.095

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-29 2025-04-29
Earnings (Next)05-28 2025-05-28
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners4.02%
Ins Owner ChangeN/A
Market Cap14.10M
Analysts84.44
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0
BVpS-0.06
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1259%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1012.86%
ROA(5y)-1608.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.04
Quick Ratio 0.04
Altman-Z -613.8
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y59.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y95.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y95.36%
OCF growth 3YN/A
OCF growth 5YN/A